Search
Tislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigational[A262924] On September 25, 2023, tislelizumab gained EMA approval as a monotherapy for adults with esophageal cancer under the brand name TEVIMBRA. … It was engineered to have a nullified Fc portion, thus minimizing binding to FcγR on macrophages and limiting treatment resistance via antibody-dependent phagocytosis.
Phentolamine
go.drugbank.com/drugs/DB00692ApprovedInvestigationalPhentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. … [A261781, A261786] It has several therapeutic uses, including the treatment of hypertensive episodes, prevention of norepinephrine-induced extravasation, diagnosis of pheochromocytoma, reversal of soft-tissue
Nirsevimab
go.drugbank.com/drugs/DB16258ApprovedInvestigational[L44146,A254571] Compared to [palivizumab], another anti-RSV antibody, nirsevimab shows greater potency at reducing pulmonary viral loads in animal models. … [A254691] This is due to a modification in the Fc region of nirsevimab that grants it a longer half-time compared to typical monoclonal antibodies.
Carteolol
go.drugbank.com/drugs/DB00521ApprovedA beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.
Saprisartan
go.drugbank.com/drugs/DB01347ExperimentalSaprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure. … The mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan.
Eslicarbazepine acetate
go.drugbank.com/drugs/DB09119ApprovedInvestigationalEslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled … Eslicarbazepine acetate is marketed as Aptiom in North America and Zebinix or Exalief in Europe. It is available in 200, 400, 600, or 800mg tablets that are taken once daily, with or without food.
Deflazacort
go.drugbank.com/drugs/DB11921ApprovedDeflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). … [A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7.
Streptococcus pneumoniae type 2 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10320ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 2 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 2 of *Streptococcus pneumoniae*.
Streptococcus pneumoniae type 8 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10326ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 8 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 8 of *Streptococcus pneumoniae*.
Streptococcus pneumoniae type 10a capsular polysaccharide antigen
go.drugbank.com/drugs/DB10329ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 10a capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 10a of *Streptococcus pneumoniae